Which has better earnings and valuation, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 105.93 -$67.85M -$0.24 N/A Moderna $1.94B 12.45 -$2.82B -$8.15 N/A

Is OCGN or MRNA more profitable?

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Moderna -143.55% -26.64% -19.32%

Does the media prefer OCGN or MRNA?

In the previous week, Moderna had 39 more articles in the media than Ocugen. MarketBeat recorded 41 mentions for Moderna and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat Moderna's score of 0.40 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 16 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PFE or OCGN?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.25 $7.77B $1.31 18.89 Ocugen $4.41M 105.93 -$67.85M -$0.24 N/A

Is PFE or OCGN more profitable?

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of -1,192.18%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Ocugen -1,192.18% -127,987.80% -135.48%

Does the media refer more to PFE or OCGN?

In the previous week, Pfizer had 81 more articles in the media than Ocugen. MarketBeat recorded 83 mentions for Pfizer and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat Pfizer's score of 0.87 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 41 Very Positive mention(s) 12 Positive mention(s) 17 Neutral mention(s) 7 Negative mention(s) 6 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ANAB or OCGN?

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 7.37 -$13.23M -$1.08 N/A Ocugen $4.41M 105.93 -$67.85M -$0.24 N/A

Is ANAB or OCGN more profitable?

AnaptysBio has a net margin of -11.53% compared to Ocugen's net margin of -1,192.18%. AnaptysBio's return on equity of -1,101.24% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% -1,101.24% -7.75% Ocugen -1,192.18% -127,987.80% -135.48%

Does the media prefer ANAB or OCGN?

In the previous week, AnaptysBio had 1 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for AnaptysBio and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat AnaptysBio's score of 1.36 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCGN or CMPS more profitable?

Compass Pathways has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Compass Pathways' return on equity of -31.07% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Compass Pathways N/A -31.07% -11.40%

Does the media refer more to OCGN or CMPS?

In the previous week, Ocugen and Ocugen both had 2 articles in the media. Ocugen's average media sentiment score of 1.45 beat Compass Pathways' score of 0.64 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCGN or AMLX more profitable?

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media prefer OCGN or AMLX?

In the previous week, Ocugen had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Ocugen and 1 mentions for Amylyx Pharmaceuticals. Ocugen's average media sentiment score of 1.45 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ocugen (OCGN) Competitors

$1.38 +0.09 (+6.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.00 (+0.29%)

As of 07:56 PM Eastern

Compare

OCGN vs. MRNA, PFE, ANAB, CMPS, and AMLX

Should you buy Ocugen stock or one of its competitors? MarketBeat compares Ocugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocugen include Moderna (MRNA), Pfizer (PFE), AnaptysBio (ANAB), Compass Pathways (CMPS), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "medical" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Ocugen has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	105.93	-$67.85M	-$0.24	N/A
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 39 more articles in the media than Ocugen. MarketBeat recorded 41 mentions for Moderna and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat Moderna's score of 0.40 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	16 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 588.41%. Moderna has a consensus target price of $36.60, indicating a potential downside of 40.00%. Given Ocugen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Ocugen beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Pfizer (NYSE:PFE) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pfizer presently has a consensus target price of $28.82, indicating a potential upside of 16.46%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 588.41%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.25	$7.77B	$1.31	18.89
Ocugen	$4.41M	105.93	-$67.85M	-$0.24	N/A

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of -1,192.18%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

In the previous week, Pfizer had 81 more articles in the media than Ocugen. MarketBeat recorded 83 mentions for Pfizer and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat Pfizer's score of 0.87 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	41 Very Positive mention(s)	12 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	6 Very Negative mention(s)	Positive
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Summary

Pfizer beats Ocugen on 11 of the 17 factors compared between the two stocks.

How does Ocugen compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, AnaptysBio had 1 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for AnaptysBio and 2 mentions for Ocugen. Ocugen's average media sentiment score of 1.45 beat AnaptysBio's score of 1.36 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.3% of Ocugen shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.37	-$13.23M	-$1.08	N/A
Ocugen	$4.41M	105.93	-$67.85M	-$0.24	N/A

AnaptysBio currently has a consensus target price of $81.82, indicating a potential upside of 37.67%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 588.41%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

AnaptysBio has a net margin of -11.53% compared to Ocugen's net margin of -1,192.18%. AnaptysBio's return on equity of -1,101.24% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

Summary

AnaptysBio beats Ocugen on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Compass Pathways?

Ocugen (NASDAQ:OCGN) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Compass Pathways has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Compass Pathways' return on equity of -31.07% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Compass Pathways	N/A	-31.07%	-11.40%

In the previous week, Ocugen and Ocugen both had 2 articles in the media. Ocugen's average media sentiment score of 1.45 beat Compass Pathways' score of 0.64 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has higher revenue and earnings than Compass Pathways. Ocugen is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	105.93	-$67.85M	-$0.24	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

10.3% of Ocugen shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ocugen has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 588.41%. Compass Pathways has a consensus price target of $22.90, suggesting a potential upside of 81.03%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Compass Pathways beats Ocugen on 9 of the 15 factors compared between the two stocks.

How does Ocugen compare to Amylyx Pharmaceuticals?

Ocugen (NASDAQ:OCGN) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Ocugen has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	105.93	-$67.85M	-$0.24	N/A
Amylyx Pharmaceuticals	$87.37M	20.83	-$144.74M	-$1.50	N/A

Ocugen currently has a consensus target price of $9.50, suggesting a potential upside of 588.41%. Amylyx Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 40.50%. Given Ocugen's higher possible upside, equities research analysts clearly believe Ocugen is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

In the previous week, Ocugen had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Ocugen and 1 mentions for Amylyx Pharmaceuticals. Ocugen's average media sentiment score of 1.45 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ocugen has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Ocugen on 9 of the 17 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$436.69M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.75	19.75	24.92	23.98
Price / Sales	105.93	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-34.50	8.29	10.79	6.50
Net Income	-$67.85M	$23.85M	$3.56B	$336.88M
7 Day Performance	16.95%	5.21%	1.67%	-0.22%
1 Month Performance	2.99%	2.19%	0.43%	0.77%
1 Year Performance	40.66%	60.99%	32.84%	31.57%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	2.9664 of 5 stars	$1.38 +7.0%	$9.50 +588.4%	+21.7%	$436.69M	$4.41M	N/A	80	Positive News
MRNA Moderna	1.2411 of 5 stars	$52.13 +4.4%	$36.60 -29.8%	+129.2%	$19.80B	$1.94B	N/A	4,700
PFE Pfizer	4.2149 of 5 stars	$26.01 -0.8%	$28.82 +10.8%	+4.6%	$149.38B	$62.58B	19.86	75,000	Trending News Analyst Upgrade
ANAB AnaptysBio	3.3795 of 5 stars	$59.51 +6.1%	$81.82 +37.5%	+158.9%	$1.63B	$234.60M	N/A	100	Positive News
CMPS Compass Pathways	3.1892 of 5 stars	$11.79 -2.4%	$21.36 +81.2%	+172.8%	$1.63B	N/A	N/A	120	News Coverage Options Volume Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors